Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 3/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441996 | 0.80 | TGFBR1 (0.47) | PDE4BMAPK9MAPK10PDE10APDE5A | |
| SCHEMBL14593062 | 0.75 | GSK3B (0.55) | MAPK9EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL5212674 | 0.74 | GSK3B (0.43) | PDE4BMAPK9MAPK10PDE10AEGFR | |
| SCHEMBL5426190 | 0.74 | MAPK9 (0.56) | PDE4BMAPK9MAPK10PDE10AGSK3B | |
| SCHEMBL13847898 | 0.72 | SLC2A1 (0.40) | PDE4BMAPK9MAPK10PDE10AEGFR | |
| SCHEMBL3442305 | 0.70 | MEN1 (0.42) | EGFR | |
| SCHEMBL5429257 | 0.67 | TGFBR1 (0.48) | PDE4BMAPK9MAPK10PDE10APDE5A | |
| SCHEMBL13044401 | 0.66 | PDE4B (0.62) | PDE4BMAPK9MAPK10PDE10APDE5A | |
| SCHEMBL5426787 | 0.65 | CDK4 (0.48) | PDE4BMAPK9MAPK10PDE10AGSK3B | |
| SCHEMBL27997668 | 0.64 | AURKA (0.50) | MAPK9MAPK10EGFRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153863-B2 | Therapeutic compounds based on pyrazolopyridline derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | claimed |
| US-20050282842-A1 | Therapeutic compounds based on pyrazolopyridine derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | claimed |
| US-20070112014-A1 | Therapeutic Compounds Based on Pyrazolopyridine | GUDMUNDSSON KRISTJAN S | 2007-05-17 | — | — | US | disclosed |
| US-20070112014-A1 | Therapeutic Compounds Based on Pyrazolopyridine | GUDMUNDSSON KRISTJAN S | 2007-05-17 | — | — | US | disclosed |
| US-20070112014-A1 | Therapeutic Compounds Based on Pyrazolopyridine | GUDMUNDSSON KRISTJAN S | 2007-05-17 | — | — | US | disclosed |
| US-7153863-B2 | Therapeutic compounds based on pyrazolopyridline derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050282842-A1 | Therapeutic compounds based on pyrazolopyridine derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282842-A1 | Therapeutic compounds based on pyrazolopyridine derivatives | CYP3A5, QDPR, DPYD | PDE4B 77/4885MAPK9 1045/4885MAPK10 2246/4885 |
| US-20070112014-A1 | Therapeutic Compounds Based on Pyrazolopyridine | CYP3A5, QDPR, DPYD | PDE4B 64/4885MAPK9 1306/4885MAPK10 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.